Mobina Oladghaffari

Mobina Oladghaffari

Auto-generated profile, based on publicly available information

Mobina Oladghaffari

Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2021 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
SRSeyed Z. Rasihashemi
Seyed Z. Rasihashemi
EGErfan Rezazadeh Gavgani
Erfan Rezazadeh Gavgani
RMReza Majidazar
Reza Majidazar
PSParya Seraji
Parya Seraji
MOMobina Oladghaffari
Mobina Oladghaffari
PLParisa Lotfinejad
Parisa Lotfinejad

20 January 2023 in Gene
Verified
Journal Article
Closed access
ERErfan Rezazadeh-Gavgani
Erfan Rezazadeh-Gavgani
MOMobina Oladghaffari
Mobina Oladghaffari
SBShirin Bahramian
Shirin Bahramian
RMReza Majidazar
Reza Majidazar
SDSanam Dolati
Sanam Dolati

1 January 2023 in International Journal of Drug Research in Clinics
Verified
Journal Article
Open access
PDF file
MOMobina Oladghaffari
Mobina Oladghaffari
SRSama Rahnemayan
Sama Rahnemayan
ZTZahra Tohid
Zahra Tohid
MMMajid Montazer
Majid Montazer
FDFarnaz Dabiri
Farnaz Dabiri
Background: This systematic review and meta-analysis assessed the data from cohort studies that compared treatment with or without incretins and the incidence of breast cancer (BC) due to the current controversies. Methods: PubMed, Scopus, EMBASE, Cochrane, ProQuest, Ovid, and Google Scholar were searched for relevant studies. A secondary analysis was conducted to compare the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4Is) on BC development. Results: The meta-analysis of four studies with 58,767 patients and 461,475 controls revealed that incretin-based therapies increase the incidence of BC insignificantly (risk ratio (RR)=1.23, 95% confidence interval (CI)=0.44–3.40; P=0.69). The DPP-4I group significantly reduced the risk of BC compared to the GLP-1RA group (RR=0.43, 95% CI=0.32–0.59; P<0.00001). Conclusion: This study found no evidence of a substantial increase in BC incidence in patients with type 2 diabetes taking GLP-1RAs and DPP-4Is. However, DPP-4Is were less likely than GLP-1RAs to cause BC formation.

20 December 2024 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
RVRoya Vatankhah
Roya Vatankhah
ARAfsaneh Radmehr
Afsaneh Radmehr
HAHamideh Azimi Alamdari
Hamideh Azimi Alamdari
FNFaeghe Sheikhalizadeh Nobar
Faeghe Sheikhalizadeh Nobar
MOMobina Oladghaffari
Mobina Oladghaffari

6 January 2026 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
MOMobina Oladghaffari
Mobina Oladghaffari
HBHeliya Bandehagh
Heliya Bandehagh
FMFatemeh Malekinejad
Fatemeh Malekinejad
SFShahrzad Fakhkhari
Shahrzad Fakhkhari
NKNarges Koohi
Narges Koohi
ANAmirreza Naseri
Amirreza Naseri
Multiple sclerosis (MS) is still under investigation for its pathogenesis. This study explores the relationship between the key circadian rhythm regulators